Atherosclerosis: One Disease, Many Conditions

A vascular surgeon explains how one systemic disease shows up across the brain, the heart, and the limbs, and why it wears so many different names.

Dr. York N. Hsiang

Phase I/II VesCell (ACP-01) Principal Investigator · Professor Emeritus, UBC

Disclosure:  Dr. Hsiang has a commercial relationship with Hemostemix Inc. 

WHY THIS MATTERS

Why does the same disease get four different names depending on which doctor you see?

A neurologist sees vascular cognitive impairment. A cardiologist sees refractory angina. A vascular surgeon sees peripheral artery disease and limb-threatening ischemia. Different specialists, different names, different departments. Yet underneath many of these conditions is a single systemic process: atherosclerosis restricting blood flow, and tissue downstream starved of what it needs.

In this on-demand session, Dr. York N. Hsiang follows that one root cause across the organs it reaches, and looks at what the research is exploring at the level of the smallest vessels.

 

WHAT YOU'LL LEARN

  • Why atherosclerosis is one systemic disease process, and how the same underlying problem gets four different names depending on which organ it reaches 

  • How impaired blood flow to the brain, the heart, the coronary circulation, and the limbs produces conditions that look unrelated but share a common root 

  • What happens downstream, at the level of the smallest vessels, when circulation fails and tissue is starved of oxygen 

  • What the research is exploring about angiogenesis, the growth of new blood vessels, at the site of ischemia 

Watch the full replay. It is free.

Enter your information below and we will send your replay link immediately.

VesCell is an investigational therapy. This webinar is for informational purposes only and does not constitute medical advice or a clinical consultation.

THIS WEEKS HOSTS
DrHsiang
Dr. York N. Hsiang, MB ChB, MHSc, FRCSC

Professor Emeritus of Surgery | Former Head of Vascular Surgery, Vancouver General Hospital | Principal Investigator, Phase II ACP‑01 Clinical Trial.

Dr. York N. Hsiang is a vascular surgeon with decades of clinical and academic experience. He is Professor Emeritus of Surgery and former Head of Vascular Surgery at Vancouver General Hospital, and serves as Principal Investigator of the Phase II ACP‑01 clinical trial. His work centers on the vascular disease process that underlies ischemia across the body. 

Hemostemix-Tom
Thomas Smeenk

President and Co-Founder, Hemostemix Inc.

Thomas Smeenk leads Hemostemix, the company developing ACP-01, an investigational autologous stem cell therapy derived from the patient's own blood. He brings together the published research, the clinical data, and the plain-language explanations that patients and families need when standard medicine stops having answers.

WHO THIS REPLAY IS FOR

This recording is for you if:

  • You or someone you care for has been diagnosed with Ischemic Conditions
  • You want to understand what the current investigational research shows
  • You have questions about whether VesCell research may be relevant to your situation 
  • You are ready to have a different kind of conversation about what is possible 

Is a Consultation right for you?

Hemostemix is pursuing LARTA authorization for VesCell therapy at Doctors Hospital, The Bahamas. A protocol-based study is under development. Understand if you or someone you care for is eligible by clicking the button below.

 

One root cause. Many conditions. One conversation worth watching.

VesCell (ACP-01) is an investigational autologous angiogenic cell therapy. It is not approved by the FDA or any other regulatory authority. This webinar is for informational purposes only and does not constitute medical advice, a treatment recommendation, or a clinical consultation. Individual patient outcomes may vary. Speak with your physician about your specific medical situation.
 
Hemostemix Inc. (TSXV: HEM | OTCQB: HMTXF | FSE: 2VF0)